MNMathew Njoroge

Mathew Njoroge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mathew Njoroge has a total of 345 co-authors. Here are the top co-authors by number of shared publications:

  • Kelly Chibale

    University of Cape Town

    39 shared publications
  • Dale Taylor

    Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa

    18 shared publications
  • Sergio Wittlin

    Swiss Tropical and Public Health Institute, Socinstraße 57, 4002 Basel, Switzerland

    14 shared publications
  • Christel Brunschwig

    Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa

    13 shared publications
  • Nina Lawrence

    Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa

    13 shared publications
  • Leslie J. Street

    Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa

    12 shared publications

Latest Publications

  • Open Access

    Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

    by Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale

    Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose for malaria is within the clinically established safety and tolerability profile. First, an oral dose fractionation study was performed in a Plasmodium falciparum ‐infected humanized mouse model to evaluate the antimalarial pharmacokinetic‐pharmacodynamic properties of berzosertib. The activity of berzosertib was shown to be strongly dependent on the time in which the concentrations remain above the minimum parasiticidal concentration (MPC). A human physiologically based pharmacokinetic model was then developed and used to simulate the exposure‐response relationships and determine the effective human dose which fulfilled the target pharmacokinetic profile of sustained concentrations above the MPC. Our prediction indicates that six daily intravenous doses of 75 mg of berzosertib will be required for the treatment of an uncomplicated blood stage malaria infection, which is comparatively lower than the clinical maximum tolerated dose for cancer therapy, which was identified as 440 mg administered intravenously twice weekly over a 21‐day cycle for up to 18 weeks. Despite berzosertib's potential for repurposing, further preclinical development is necessary to ensure it meets the standard of current and emerging antimalarials.


  • Open Access

    Artificial intelligence coupled to pharmacometrics modelling to tailor malaria and tuberculosis treatment in Africa

    by Gemma Turon, Mwila Mulubwa, Anna Montaner, Mathew Njoroge, Kelly Chibale, Miquel Duran-Frigola

    Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Our pipeline couples machine learning and artificial intelligence with physiologically-based pharmacokinetic (PBPK) and non-linear mixed effects (NLME) modelling to hypothesize which pharmacogenes could be of potential clinical interest, and which dose adjustments could be made to provide better treatment outcomes for African populations. Drug-gene pairs are first ranked with the latest knowledge embedding techniques, based on public structural and bioactivity data for drugs and genes, followed by a large language model-based refinement. Selected genes are then evaluated for their sensitivity in PBPK analysis, and relevant variants subsequently inspected with NLME for dose optimization. The analysis is focused on genes with potential clinical relevance in Africa. We delve deeper into malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective.


  • Open Access

    Structure−Activity Relationship and Antituberculosis Properties of 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 Inhibitors

    by Lutete Peguy Khonde, Nashied Peton, Keabetswe Masike, Tanya Valentine, Frank Zindo, Stephen Fienberg, Charles Omollo, Mathew Njoroge, Francesco Vallini, Chiara Tammaro, et al.

  • Open Access

    In Life Behavior of Praziquantel and Relationship Between Drug Exposure and Effect

    by Mathew Njoroge, Peter Ballard

    In this chapter, the pharmacokinetics of praziquantel will be discussed, covering key data and parameters related to how the drug is absorbed, distributed, metabolized, and excreted. Additionally, the relationship between the drug’s exposure and its pharmacodynamic effects will be examined.

  • Open Access

    CYP1A2 contributes to the metabolism of mefloquine: Exploration using in vitro metabolism and physiologically-based pharmacokinetic modelling

    by Cleavon K. Cloete, Preshendren Govender, Nicholas Njuguna, Neil J. Parrott, Kenichi Umehara, Kelly Chibale, Mathew Njoroge

  • Open Access

    Synthesis and SAR Studies of Acyl-Thiourea Platinum(II) Complexes Yield Analogs with Dual-Stage Antiplasmodium Activity

    by Fatima-Zahra Ishmail, Dina Coertzen, Sizwe Tshabalala, Meta Leshabane, Shante da Rocha, Mathew Njoroge, Liezl Gibhard, Lyn-Marie Birkholtz, John G. Woodland, Timothy J. Egan, et al.

    Mixed-ligand platinum(II) complexes incorporating bipyridine and acyl-thiourea ligands were synthesized and evaluated for their in vitro growth inhibitory activity against the human malaria parasite Plasmodium falciparum (Pf). The substituents at four distinct sites were varied to identify structure-activity relationships for this series. Most complexes displayed potent PfNF54 activity with IC50 values in the nanomolar range and favorable cytotoxicity profiles. Five complexes (C1, C11, C12, C15, and C17) exhibited activity against both the asexual blood and sexual (gametocyte) stage parasites, with another complex (C8) exhibiting activity against late-stage gametocytes only. In addition, the complexes showed comparable ABS potency against the PfK1 multidrug-resistant strain. The pharmacokinetic parameters of one analog (C6), which displayed good solubility and mouse microsomal metabolic stability, were measured. This work demonstrates the potential of acyl-thiourea platinum(II) complexes as selective, multistage-active antiplasmodium compounds as part of the search for new antimalarial agents.


  • Open Access

    Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials

    by Mariska Naude, Ashleigh van Heerden, Janette Reader, Mariëtte van der Watt, Jandeli Niemand, Dorè Joubert, Giulia Siciliano, Pietro Alano, Mathew Njoroge, Kelly Chibale, et al.

    Novel antimalarial compounds targeting both the pathogenic and transmissible stages of the human malaria parasite, Plasmodium falciparum, would greatly benefit malaria elimination strategies. However, most compounds affecting asexual blood stage parasites show severely reduced activity against gametocytes. The impact of this activity loss on a compound’s transmission-blocking activity is unclear. Here, we report the systematic evaluation of the activity loss against gametocytes and investigate the confounding factors contributing to this. A threshold for acceptable activity loss between asexual blood stage parasites and gametocytes was defined, with near-equipotent compounds required to prevent continued gametocyte maturation and onward transmission. Target abundance is not predictive of gametocytocidal activity, but instead, lipoidal uptake is the main barrier of dual activity and is influenced by distinct physicochemical properties. This study provides guidelines for the required profiles of potential dual-active antimalarial agents and facilitates the development of effective transmission-blocking compounds.


  • Open Access

    AI coupled to pharmacometric modelling to tailor malaria and tuberculosis treatment in Africa

    by Gemma Turon, Mwila Mulubwa, Anna Montaner, Mathew Njoroge, Kelly Chibale, Miquel Duran-Frigola

    Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Furthermore, we delve deeper into the analysis of malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective. Our pipeline leverages artificial intelligence and the latest advances in knowledge embedding techniques to exploit currently available biomedical data and subsequently prioritise pharmacogenes for each drug. Predicted pharmacogenes are then incorporated into pharmacometric modelling to hypothesise which ones might be of clinical interest, and which dose adjustments could be made to provide better treatment outcomes for the African population.

  • Open Access

    2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of Plasmodium falciparum Phosphatidylinositol-4-kinase and Hemozoin Formation with In Vivo Efficacy

    by Godwin Akpeko Dziwornu, Donald Seanego, Stephen Fienberg, Monica Clements, Jasmin Ferreira, Venkata S. Sypu, Sauvik Samanta, Ashlyn D. Bhana, Constance M. Korkor, Larnelle F. Garnie, et al.

    Structure-activity relationship studies of 2,8-disubstituted-1,5-naphthyridines, previously reported as potent inhibitors of Plasmodium falciparum (Pf) phosphatidylinositol-4-kinase β (PI4K), identified 1,5-naphthyridines with basic groups at 8-position, which retained Plasmodium PI4K inhibitory activity but switched primary mode of action to the host hemoglobin degradation pathway through inhibition of hemozoin formation. These compounds showed minimal off-target inhibitory activity against the human phosphoinositide kinases and MINK1 and MAP4K kinases, which were associated with the teratogenicity and testicular toxicity observed in rats for the PfPI4K inhibitor clinical candidate MMV390048. A representative compound from the series retained activity against field isolates and lab-raised drug-resistant strains of Pf. It was efficacious in the humanized NSG mouse malaria infection model at a single oral dose of 32 mg/kg. This compound was nonteratogenic in the zebrafish embryo model of teratogenicity and has a low predicted human dose, indicating that this series has the potential to deliver a preclinical candidate for malaria.